Renewed multi-year partnership to support
Ferring Pharmaceuticals' operations in response to rapid business
growth
NEW
YORK, Nov. 21, 2024 /PRNewswire/ -- Genpact
(NYSE: G), a global professional services and solutions firm
delivering outcomes that shape the future, today announced the
extension of its partnership with Ferring Pharmaceuticals, a
research-driven biopharmaceutical company that has operating
subsidiaries in more than 50 countries and markets its medicines in
over 100 countries. The renewed multi-year agreement will continue
the transformation of Ferring's finance, accounting, and
procurement operations with advanced technologies, including
AI.
"To drive growth in a complex and competitive environment,
pharmaceutical companies need modern, scalable and efficient
solutions," said Sanjiv Tandon,
Global Head of Life Sciences and Healthcare, Genpact. "Our
ongoing partnership with Ferring Pharmaceuticals leverages our
industry expertise and a shared vision to harness advanced
technologies, setting a new standard for innovation and enabling
Ferring to meet evolving demands with speed and accuracy."
Under the agreement, Genpact will continue to streamline
workflows, optimize resource allocation, and improve the accuracy
and speed of financial transactions. In collaboration with
technology partners like Xelix and Blackline, Genpact will automate
key processes, such as invoice management and procurement
workflows, while establishing robust data analytics capabilities
for real-time financial insights. These enhancements aim to deliver
significant operational savings and enable Ferring to adapt swiftly
to evolving customer and patient needs.
"Our partnership with Genpact spans over 40 digital
transformation projects, with a strong focus on AI applications,"
said Dominic Moorhead, Chief
Financial Officer, Ferring Pharmaceuticals. "By standardizing
processes and leveraging advanced technologies, like AI, we're
enhancing accuracy, real-time insights, and overall efficiency to
support our purpose of building families and helping people live
better lives."
This collaboration underscores Ferring Pharmaceuticals'
commitment to innovation, enabling the company to thrive and
deliver its range of innovative treatments to change the lives of
people and families around the world.
To learn more about Genpact's solutions and services for
Healthcare and Life Sciences industries, click here.
About Genpact
Genpact (NYSE: G) is a global professional services and
solutions firm delivering outcomes that shape the future. Our
125,000+ people across 30+ countries are driven by our innate
curiosity, entrepreneurial agility, and desire to create lasting
value for clients. Powered by our purpose – the relentless pursuit
of a world that works better for people – we serve and transform
leading enterprises, including the Fortune Global 500, with our
deep business and industry knowledge, digital operations services,
and expertise in data, technology, and AI.
Get to know us at genpact.com and
on LinkedIn, X, YouTube,
and Facebook.
MEDIA CONTACT:
Sue
Martenson
Genpact Media Relations
+1
978-905-9582
susan.martenson@genpact.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genpact-announces-renewed-partnership-with-ferring-pharmaceuticals-302312504.html
SOURCE Genpact Ltd.
